Company intelligence / Profile preview

EyebioKorea

Busanjin-gu, Busan, South Koreapublications.gc.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

EB‑203 is in Phase II clinical trials for wet AMD. It is administered as an ophthalmic eye drop and targets both VEGF and PEDF pathways. No published efficacy results are available yet; the program remains investigational.

Therapeutic areas: OphthalmologyEndocrinology
Modalities: Synthetic peptidesSmall moleculesBiologics
Industry: Biotech

Partnerships

No specific major pharmaceutical partnerships disclosed publicly as of May 2025. The company collaborates with various research institutes and pharmaceutical companies on technology development.

Beyond the preview

Go deeper on EyebioKorea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyebioKorea.

Explore the full profile